Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
22
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Thomas Dolca | Chief Medical Officer | 13 | $0 | $2.73M | 2020-09-28 |
| Becker Daniel J. | Director, 10% Owner | 22 | $23.81M | $0 | 2020-09-28 |
| Wolff Stefani | Chief Development Officer | 25 | $0 | $1.39M | 2020-09-28 |
| Goldstein David M | Chief Scientific Officer | 39 | $0 | $1.64M | 2020-09-28 |
| Lin Shao-Lee | Director | 6 | $0 | $0 | 2020-09-28 |
| Tomasello Shawn | Director | 6 | $0 | $0 | 2020-09-28 |
| George Simeon | Director, 10% Owner | 20 | $14.59M | $0 | 2020-09-28 |
| Hardiman Roy C. | Chief Business Officer | 29 | $0 | $1.30M | 2020-09-28 |
| Babler Martin | President, CEO | 45 | $0 | $3.45M | 2020-09-28 |
| CHAI CHRISTOPHER Y | Chief Financial Officer | 26 | $0 | $1.73M | 2020-09-28 |
| Colowick Alan | Director | 16 | $0 | $900.1K | 2020-09-28 |
| Machado Patrick | Director | 6 | $0 | $0 | 2020-09-28 |
| BVF PARTNERS L P/IL | 10% Owner | 3 | $81.2K | $0 | 2020-08-18 |
| GLAXOSMITHKLINE PLC | Other | 14 | $14.59M | $0 | 2019-10-18 |
| New Leaf Ventures II, L.P. | 10% Owner | 13 | $4.59M | $10.50M | 2019-08-13 |
| OrbiMed Capital GP IV LLC | 10% Owner | 1 | $0 | $30.25M | 2019-05-21 |
| Smither John W | Director | 1 | $0 | $0 | 2019-02-19 |
| Gourlay Steve | Chief Medical Officer | 2 | $0 | $0 | 2018-09-18 |
| Mehra Anand | 10% Owner | 9 | $4.59M | $0 | 2018-09-18 |
| AKKARAJU SRINIVAS | Director | 4 | $2.98M | $0 | 2018-09-18 |
| ORBIMED ADVISORS LLC | 10% Owner | 11 | $4.25M | $0 | 2018-09-18 |
| Shuster Lewis | Director | 1 | $0 | $0 | 2018-09-13 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Babler Martin | President, CEO | D To issuer deriv | 2020-09-28 | 2020-09-28 | 115,590 | — | $0 | 0 | SEC↗ |
| Babler Martin | President, CEO | D To issuer deriv | 2020-09-28 | 2020-09-28 | 60,546 | — | $0 | 0 | SEC↗ |
| Babler Martin | President, CEO | D To issuer deriv | 2020-09-28 | 2020-09-28 | 187,144 | — | $0 | 0 | SEC↗ |
| Babler Martin | President, CEO | D To issuer deriv | 2020-09-28 | 2020-09-28 | 155,000 | — | $0 | 0 | SEC↗ |
| Babler Martin | President, CEO | D To issuer deriv | 2020-09-28 | 2020-09-28 | 200,000 | — | $0 | 0 | SEC↗ |
| Babler Martin | President, CEO | D To issuer deriv | 2020-09-28 | 2020-09-28 | 255 | — | $0 | 0 | SEC↗ |
| Babler Martin | President, CEO | D To issuer deriv | 2020-09-28 | 2020-09-28 | 50,795 | — | $0 | 0 | SEC↗ |
| Babler Martin | President, CEO | D To issuer deriv | 2020-09-28 | 2020-09-28 | 85,728 | — | $0 | 0 | SEC↗ |
| Babler Martin | President, CEO | D To issuer deriv | 2020-09-28 | 2020-09-28 | 110,085 | — | $0 | 0 | SEC↗ |
| Babler Martin | President, CEO | D To issuer deriv | 2020-09-28 | 2020-09-28 | 83,004 | — | $0 | 0 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 60,000 | — | $0 | 0 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 75,000 | — | $0 | 0 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 44,034 | — | $0 | 0 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 34,677 | — | $0 | 0 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 12,960 | — | $0 | 0 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 13,210 | — | $0 | 0 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 8,807 | — | $0 | 0 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 15,412 | — | $0 | 0 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 22,017 | — | $0 | 0 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 34,677 | — | $0 | 0 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 13,210 | — | $0 | 0 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 29,723 | — | $0 | 0 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 24,769 | — | $0 | 0 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 56,982 | — | $0 | 0 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 55,000 | — | $0 | 0 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 60,000 | — | $0 | 0 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 44,034 | — | $0 | 0 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 60,000 | — | $0 | 0 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 44,034 | — | $0 | 0 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 55,000 | — | $0 | 0 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 11,519 | — | $0 | 0 | SEC↗ |
| Thomas Dolca | Chief Medical Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 168,057 | — | $0 | 0 | SEC↗ |
| Thomas Dolca | Chief Medical Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 60,000 | — | $0 | 0 | SEC↗ |
| Thomas Dolca | Chief Medical Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 55,000 | — | $0 | 0 | SEC↗ |
| Wolff Stefani | Chief Development Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 22,017 | — | $0 | 0 | SEC↗ |
| Wolff Stefani | Chief Development Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 16,843 | — | $0 | 0 | SEC↗ |
| Wolff Stefani | Chief Development Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 55,042 | — | $0 | 0 | SEC↗ |
| Wolff Stefani | Chief Development Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 55,000 | — | $0 | 0 | SEC↗ |
| Wolff Stefani | Chief Development Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 60,000 | — | $0 | 0 | SEC↗ |
| Wolff Stefani | Chief Development Officer | D To issuer deriv | 2020-09-28 | 2020-09-28 | 30,056 | — | $0 | 0 | SEC↗ |
| Colowick Alan | Director | D To issuer deriv | 2020-09-28 | 2020-09-28 | 10,240 | — | $0 | 0 | SEC↗ |
| Colowick Alan | Director | D To issuer deriv | 2020-09-28 | 2020-09-28 | 10,240 | — | $0 | 0 | SEC↗ |
| Colowick Alan | Director | D To issuer deriv | 2020-09-28 | 2020-09-28 | 47,724 | — | $0 | 0 | SEC↗ |
| Colowick Alan | Director | D To issuer deriv | 2020-09-28 | 2020-09-28 | 20,475 | — | $0 | 0 | SEC↗ |
| Becker Daniel J. | Director | D To issuer deriv | 2020-09-28 | 2020-09-28 | 10,240 | — | $0 | 0 | SEC↗ |
| Becker Daniel J. | Director | D To issuer deriv | 2020-09-28 | 2020-09-28 | 10,240 | — | $0 | 0 | SEC↗ |
| Becker Daniel J. | Director | D To issuer deriv | 2020-09-28 | 2020-09-28 | 20,475 | — | $0 | 0 | SEC↗ |
| Lin Shao-Lee | Director | D To issuer deriv | 2020-09-28 | 2020-09-28 | 20,475 | — | $0 | 0 | SEC↗ |
| Lin Shao-Lee | Director | D To issuer deriv | 2020-09-28 | 2020-09-28 | 10,240 | — | $0 | 0 | SEC↗ |
| Lin Shao-Lee | Director | D To issuer deriv | 2020-09-28 | 2020-09-28 | 10,240 | — | $0 | 0 | SEC↗ |
| George Simeon | Director | D To issuer deriv | 2020-09-28 | 2020-09-28 | 10,240 | — | $0 | 0 | SEC↗ |
| George Simeon | Director | D To issuer deriv | 2020-09-28 | 2020-09-28 | 20,475 | — | $0 | 0 | SEC↗ |
| George Simeon | Director | D To issuer deriv | 2020-09-28 | 2020-09-28 | 28,623 | — | $0 | 0 | SEC↗ |
| George Simeon | Director | D To issuer deriv | 2020-09-28 | 2020-09-28 | 10,240 | — | $0 | 0 | SEC↗ |
| Machado Patrick | Director | D To issuer deriv | 2020-09-28 | 2020-09-28 | 20,475 | — | $0 | 0 | SEC↗ |
| Machado Patrick | Director | D To issuer deriv | 2020-09-28 | 2020-09-28 | 10,240 | — | $0 | 0 | SEC↗ |
| Machado Patrick | Director | D To issuer deriv | 2020-09-28 | 2020-09-28 | 10,240 | — | $0 | 0 | SEC↗ |
| Tomasello Shawn | Director | D To issuer deriv | 2020-09-28 | 2020-09-28 | 10,240 | — | $0 | 0 | SEC↗ |
| Tomasello Shawn | Director | D To issuer deriv | 2020-09-28 | 2020-09-28 | 20,475 | — | $0 | 0 | SEC↗ |
| Babler Martin | President, CEO | U Tender | 2020-09-28 | 2020-09-28 | 1,023 | $100.00 | $102.3K | 0 | SEC↗ |
| Babler Martin | President, CEO | U Tender | 2020-09-28 | 2020-09-28 | 18,355 | $100.00 | $1.84M | 0 | SEC↗ |
| Babler Martin | President, CEO | U Tender | 2020-09-28 | 2020-09-28 | 39,179 | $100.00 | $3.92M | 0 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | U Tender | 2020-09-28 | 2020-09-28 | 31,826 | $100.00 | $3.18M | 0 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | U Tender | 2020-09-28 | 2020-09-28 | 3,799 | $100.00 | $379.9K | 0 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | U Tender | 2020-09-28 | 2020-09-28 | 3,302 | $100.00 | $330.2K | 0 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | U Tender | 2020-09-28 | 2020-09-28 | 1,916 | $100.00 | $191.6K | 0 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | U Tender | 2020-09-28 | 2020-09-28 | 117,761 | $100.00 | $11.78M | 0 | SEC↗ |
| Thomas Dolca | Chief Medical Officer | U Tender | 2020-09-28 | 2020-09-28 | 2,207 | $100.00 | $220.7K | 0 | SEC↗ |
| Wolff Stefani | Chief Development Officer | U Tender | 2020-09-28 | 2020-09-28 | 13,592 | $100.00 | $1.36M | 0 | SEC↗ |
| Becker Daniel J. | Director | U Tender | 2020-09-28 | 2020-09-28 | 667,600 | $100.00 | $66.76M | 0 | SEC↗ |
| George Simeon | Director | U Tender | 2020-09-28 | 2020-09-28 | 2,982,855 | $100.00 | $298.29M | 0 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | M Exercise deriv | 2020-09-18 | 2020-09-22 | 2,242 | — | $0 | 11,519 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | M Exercise deriv | 2020-09-18 | 2020-09-22 | 2,758 | — | $0 | 0 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | S Sale | 2020-09-18 | 2020-09-22 | 5,000 | $99.98 | $499.9K | 117,761 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | M Exercise | 2020-09-18 | 2020-09-22 | 2,242 | $7.27 | $16.3K | 122,761 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | M Exercise | 2020-09-18 | 2020-09-22 | 2,758 | $4.72 | $13.0K | 120,519 | SEC↗ |
| Wolff Stefani | Chief Development Officer | G Gift | 2020-09-18 | 2020-09-28 | 5,504 | — | $0 | 13,592 | SEC↗ |
| BVF PARTNERS L P/IL | 10% Owner | P Buy deriv | 2020-08-18 | 2020-08-20 | 1,205 | $35.79 | $43.1K | 27,265 | SEC↗ |
| BVF PARTNERS L P/IL | 10% Owner | P Buy deriv | 2020-08-18 | 2020-08-20 | 158 | $35.79 | $5.7K | 3,547 | SEC↗ |
| BVF PARTNERS L P/IL | 10% Owner | P Buy deriv | 2020-08-18 | 2020-08-20 | 905 | $35.79 | $32.4K | 20,390 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | M Exercise deriv | 2020-08-18 | 2020-08-20 | 7,500 | — | $0 | 56,982 | SEC↗ |
| Thomas Dolca | Chief Medical Officer | M Exercise deriv | 2020-08-18 | 2020-08-20 | 15,000 | — | $0 | 168,057 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | M Exercise | 2020-08-18 | 2020-08-20 | 7,500 | $3.00 | $22.5K | 11,039 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | S Sale | 2020-08-18 | 2020-08-20 | 7,500 | $99.37 | $745.3K | 3,539 | SEC↗ |
| Thomas Dolca | Chief Medical Officer | S Sale | 2020-08-18 | 2020-08-20 | 15,000 | $100.00 | $1.50M | 1,826 | SEC↗ |
| Thomas Dolca | Chief Medical Officer | M Exercise | 2020-08-18 | 2020-08-20 | 15,000 | $23.77 | $356.6K | 16,826 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | M Exercise deriv | 2020-08-10 | 2020-08-12 | 3,553 | — | $0 | 12,960 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | M Exercise deriv | 2020-08-10 | 2020-08-12 | 2,447 | — | $0 | 0 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | S Sale | 2020-08-10 | 2020-08-12 | 858 | $86.11 | $73.9K | 36,881 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | M Exercise | 2020-08-10 | 2020-08-12 | 3,553 | $3.18 | $11.3K | 37,739 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | M Exercise | 2020-08-10 | 2020-08-12 | 2,447 | $3.00 | $7.3K | 34,186 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | S Sale | 2020-08-10 | 2020-08-12 | 100 | $93.34 | $9.3K | 31,739 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | S Sale | 2020-08-10 | 2020-08-12 | 1,108 | $90.99 | $100.8K | 31,839 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | S Sale | 2020-08-10 | 2020-08-12 | 700 | $89.68 | $62.8K | 32,947 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | S Sale | 2020-08-10 | 2020-08-12 | 2,534 | $88.40 | $224.0K | 33,647 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | S Sale | 2020-08-10 | 2020-08-12 | 700 | $86.92 | $60.8K | 36,181 | SEC↗ |
| Thomas Dolca | Chief Medical Officer | M Exercise deriv | 2020-07-15 | 2020-07-17 | 15,000 | — | $0 | 183,057 | SEC↗ |
| Thomas Dolca | Chief Medical Officer | M Exercise | 2020-07-15 | 2020-07-17 | 15,000 | $23.77 | $356.6K | 16,826 | SEC↗ |
| Thomas Dolca | Chief Medical Officer | S Sale | 2020-07-15 | 2020-07-17 | 15,000 | $80.07 | $1.20M | 1,826 | SEC↗ |
| Colowick Alan | Director | M Exercise deriv | 2020-07-01 | 2020-07-02 | 7,500 | — | $0 | 47,724 | SEC↗ |
| Colowick Alan | Director | M Exercise | 2020-07-01 | 2020-07-02 | 7,500 | $4.54 | $34.0K | 7,500 | SEC↗ |
| Colowick Alan | Director | S Sale | 2020-07-01 | 2020-07-02 | 7,500 | $60.00 | $450.0K | 0 | SEC↗ |
| Babler Martin | President, CEO | M Exercise deriv | 2020-06-23 | 2020-06-25 | 15,000 | — | $0 | 85,728 | SEC↗ |
| Babler Martin | President, CEO | S Sale | 2020-06-23 | 2020-06-25 | 11,983 | $61.82 | $740.8K | 3,312 | SEC↗ |
| Babler Martin | President, CEO | M Exercise | 2020-06-23 | 2020-06-25 | 15,000 | $3.00 | $45.0K | 15,810 | SEC↗ |
| Babler Martin | President, CEO | S Sale | 2020-06-23 | 2020-06-25 | 515 | $60.32 | $31.1K | 15,295 | SEC↗ |
| Babler Martin | President, CEO | S Sale | 2020-06-23 | 2020-06-25 | 2,502 | $62.38 | $156.1K | 810 | SEC↗ |
| Wolff Stefani | Chief Development Officer | S Sale | 2020-06-15 | 2020-06-17 | 100 | $61.37 | $6.1K | 19,096 | SEC↗ |
| Wolff Stefani | Chief Development Officer | S Sale | 2020-06-15 | 2020-06-17 | 400 | $59.89 | $24.0K | 24,200 | SEC↗ |
| Wolff Stefani | Chief Development Officer | S Sale | 2020-06-15 | 2020-06-17 | 5,004 | $60.81 | $304.3K | 19,196 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | M Exercise deriv | 2020-06-12 | 2020-06-15 | 5,000 | — | $0 | 2,758 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | S Sale | 2020-06-12 | 2020-06-15 | 863 | $62.13 | $53.6K | 117,761 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | M Exercise | 2020-06-12 | 2020-06-15 | 5,000 | $4.72 | $23.6K | 122,761 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | S Sale | 2020-06-12 | 2020-06-15 | 1,595 | $59.90 | $95.5K | 121,166 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | S Sale | 2020-06-12 | 2020-06-15 | 2,542 | $61.62 | $156.6K | 118,624 | SEC↗ |
| Colowick Alan | Director | A Award deriv | 2020-06-04 | 2020-06-08 | 10,240 | — | $0 | 10,240 | SEC↗ |
| Becker Daniel J. | Director | A Award deriv | 2020-06-04 | 2020-06-08 | 10,240 | — | $0 | 10,240 | SEC↗ |
| Lin Shao-Lee | Director | A Award deriv | 2020-06-04 | 2020-06-08 | 10,240 | — | $0 | 10,240 | SEC↗ |
| George Simeon | Director | A Award deriv | 2020-06-04 | 2020-06-08 | 10,240 | — | $0 | 10,240 | SEC↗ |
| Machado Patrick | Director | A Award deriv | 2020-06-04 | 2020-06-08 | 10,240 | — | $0 | 10,240 | SEC↗ |
| Tomasello Shawn | Director | A Award deriv | 2020-06-04 | 2020-06-08 | 10,240 | — | $0 | 10,240 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | M Exercise deriv | 2020-05-19 | 2020-05-21 | 5,675 | — | $0 | 64,482 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | S Sale | 2020-05-19 | 2020-05-21 | 7,500 | $65.10 | $488.2K | 3,539 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | M Exercise | 2020-05-19 | 2020-05-21 | 5,675 | $3.00 | $17.0K | 11,039 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | M Exercise deriv | 2020-05-07 | 2020-05-08 | 6,000 | — | $0 | 2,447 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | M Exercise | 2020-05-07 | 2020-05-08 | 6,000 | $3.00 | $18.0K | 36,968 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | S Sale | 2020-05-07 | 2020-05-08 | 3,281 | $59.96 | $196.7K | 33,687 | SEC↗ |
| Goldstein David M | Chief Scientific Officer | S Sale | 2020-05-07 | 2020-05-08 | 2,719 | $60.39 | $164.2K | 30,968 | SEC↗ |
| Colowick Alan | Director | M Exercise deriv | 2020-05-05 | 2020-05-05 | 6,660 | — | $0 | 55,224 | SEC↗ |
| Colowick Alan | Director | S Sale | 2020-05-05 | 2020-05-05 | 6,660 | $60.00 | $399.6K | 0 | SEC↗ |
| Colowick Alan | Director | M Exercise | 2020-05-05 | 2020-05-05 | 6,660 | $4.54 | $30.2K | 6,660 | SEC↗ |
| Colowick Alan | Director | M Exercise deriv | 2020-05-01 | 2020-05-05 | 840 | — | $0 | 61,884 | SEC↗ |
| Colowick Alan | Director | S Sale | 2020-05-01 | 2020-05-05 | 840 | $60.07 | $50.5K | 0 | SEC↗ |
| Colowick Alan | Director | M Exercise | 2020-05-01 | 2020-05-05 | 840 | $4.54 | $3.8K | 840 | SEC↗ |
| Wolff Stefani | Chief Development Officer | S Sale | 2020-03-16 | 2020-06-17 | 3,750 | $46.36 | $173.8K | 24,600 | SEC↗ |
| Wolff Stefani | Chief Development Officer | S Sale | 2020-03-16 | 2020-06-17 | 1,754 | $45.72 | $80.2K | 28,350 | SEC↗ |
| Wolff Stefani | Chief Development Officer | M Exercise deriv | 2020-03-16 | 2020-03-18 | 5,504 | — | $0 | 19,047 | SEC↗ |
| Wolff Stefani | Chief Development Officer | S Sale | 2020-03-16 | 2020-03-18 | 3,750 | $46.36 | $173.8K | 35,609 | SEC↗ |
| Wolff Stefani | Chief Development Officer | M Exercise | 2020-03-16 | 2020-03-18 | 5,504 | $4.54 | $25.0K | 41,113 | SEC↗ |
| Wolff Stefani | Chief Development Officer | S Sale | 2020-03-16 | 2020-03-18 | 1,754 | $45.72 | $80.2K | 39,359 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | M Exercise deriv | 2020-03-13 | 2020-03-17 | 5,000 | — | $0 | 7,758 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | S Sale | 2020-03-13 | 2020-03-17 | 100 | $51.04 | $5.1K | 116,903 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | M Exercise | 2020-03-13 | 2020-03-17 | 5,000 | $4.72 | $23.6K | 121,903 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | S Sale | 2020-03-13 | 2020-03-17 | 3,719 | $48.21 | $179.3K | 118,184 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | S Sale | 2020-03-13 | 2020-03-17 | 1,181 | $49.46 | $58.4K | 117,003 | SEC↗ |
| Babler Martin | President, CEO | A Award deriv | 2020-03-05 | 2020-03-05 | 200,000 | — | $0 | 200,000 | SEC↗ |
| Goldstein David | Chief Scientific Officer | A Award deriv | 2020-03-05 | 2020-03-05 | 75,000 | — | $0 | 75,000 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | A Award deriv | 2020-03-05 | 2020-03-05 | 55,000 | — | $0 | 55,000 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | A Award deriv | 2020-03-05 | 2020-03-05 | 55,000 | — | $0 | 55,000 | SEC↗ |
| Thomas Dolca | Chief Medical Officer | A Award deriv | 2020-03-05 | 2020-03-05 | 55,000 | — | $0 | 55,000 | SEC↗ |
| Wolff Stefani | Chief Development Officer | A Award deriv | 2020-03-05 | 2020-03-05 | 55,000 | — | $0 | 55,000 | SEC↗ |
| Babler Martin | President, CEO | S Sale | 2020-03-03 | 2020-03-05 | 2,085 | $62.45 | $130.2K | 52,094 | SEC↗ |
| Babler Martin | President, CEO | S Sale | 2020-03-03 | 2020-03-05 | 7,183 | $63.24 | $454.3K | 44,911 | SEC↗ |
| Babler Martin | President, CEO | S Sale | 2020-03-03 | 2020-03-05 | 300 | $64.83 | $19.4K | 39,179 | SEC↗ |
| Babler Martin | President, CEO | S Sale | 2020-03-03 | 2020-03-05 | 5,432 | $64.10 | $348.2K | 39,479 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | M Exercise deriv | 2020-02-18 | 2020-02-20 | 2,500 | — | $0 | 70,157 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | S Sale | 2020-02-18 | 2020-02-20 | 2,240 | $68.13 | $152.6K | 4,842 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | M Exercise | 2020-02-18 | 2020-02-20 | 2,500 | $3.00 | $7.5K | 12,266 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | S Sale | 2020-02-18 | 2020-02-20 | 2,684 | $63.86 | $171.4K | 9,582 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | S Sale | 2020-02-18 | 2020-02-20 | 545 | $64.91 | $35.4K | 9,037 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | S Sale | 2020-02-18 | 2020-02-20 | 1,350 | $65.94 | $89.0K | 7,687 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | S Sale | 2020-02-18 | 2020-02-20 | 76 | $68.52 | $5.2K | 4,766 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | S Sale | 2020-02-18 | 2020-02-20 | 605 | $67.08 | $40.6K | 7,082 | SEC↗ |
| Goldstein David | Chief Scientific Officer | M Exercise deriv | 2020-02-10 | 2020-02-12 | 6,000 | — | $0 | 8,447 | SEC↗ |
| Goldstein David | Chief Scientific Officer | S Sale | 2020-02-10 | 2020-02-12 | 5,200 | $71.11 | $369.8K | 30,968 | SEC↗ |
| Goldstein David | Chief Scientific Officer | S Sale | 2020-02-10 | 2020-02-12 | 800 | $69.53 | $55.6K | 36,168 | SEC↗ |
| Goldstein David | Chief Scientific Officer | M Exercise | 2020-02-10 | 2020-02-12 | 6,000 | $3.00 | $18.0K | 36,968 | SEC↗ |
| Babler Martin | President, CEO | G Gift | 2020-02-10 | 2020-03-05 | 1,159 | — | $0 | 0 | SEC↗ |
| Babler Martin | President, CEO | G Gift | 2020-02-10 | 2020-03-05 | 1,159 | — | $0 | 18,355 | SEC↗ |
| Thomas Dolca | Chief Medical Officer | S Sale | 2019-12-19 | 2019-12-20 | 495 | $60.00 | $29.7K | 494 | SEC↗ |
| Babler Martin | President, CEO | S Sale | 2019-12-18 | 2019-12-19 | 1,295 | $54.28 | $70.3K | 15,696 | SEC↗ |
| Babler Martin | President, CEO | S Sale | 2019-12-18 | 2019-12-19 | 1,000 | $52.77 | $52.8K | 19,196 | SEC↗ |
| Babler Martin | President, CEO | S Sale | 2019-12-18 | 2019-12-19 | 2,205 | $53.69 | $118.4K | 16,991 | SEC↗ |
| Babler Martin | President, CEO | S Sale | 2019-12-17 | 2019-12-19 | 5,840 | $51.80 | $302.5K | 73,339 | SEC↗ |
| Babler Martin | President, CEO | S Sale | 2019-12-17 | 2019-12-19 | 11,485 | $52.86 | $607.1K | 61,854 | SEC↗ |
| Babler Martin | President, CEO | S Sale | 2019-12-17 | 2019-12-19 | 6,661 | $53.94 | $359.3K | 55,193 | SEC↗ |
| Babler Martin | President, CEO | S Sale | 2019-12-17 | 2019-12-19 | 1,014 | $54.36 | $55.1K | 54,179 | SEC↗ |
| Wolff Stefani | Chief Development Officer | S Sale | 2019-12-16 | 2020-06-17 | 4,205 | $49.29 | $207.3K | 31,404 | SEC↗ |
| Wolff Stefani | Chief Development Officer | S Sale | 2019-12-16 | 2020-06-17 | 1,300 | $49.87 | $64.8K | 30,104 | SEC↗ |
| Wolff Stefani | Chief Development Officer | M Exercise deriv | 2019-12-16 | 2019-12-18 | 5,505 | — | $0 | 24,551 | SEC↗ |
| Wolff Stefani | Chief Development Officer | M Exercise | 2019-12-16 | 2019-12-18 | 5,505 | $4.54 | $25.0K | 41,114 | SEC↗ |
| Wolff Stefani | Chief Development Officer | S Sale | 2019-12-16 | 2019-12-18 | 4,205 | $49.29 | $207.3K | 36,909 | SEC↗ |
| Wolff Stefani | Chief Development Officer | S Sale | 2019-12-16 | 2019-12-18 | 1,300 | $49.87 | $64.8K | 35,609 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | M Exercise deriv | 2019-12-13 | 2019-12-13 | 871 | — | $0 | 12,758 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | M Exercise deriv | 2019-12-13 | 2019-12-13 | 4,129 | — | $0 | 0 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | S Sale | 2019-12-13 | 2019-12-13 | 1,619 | $49.83 | $80.7K | 120,143 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | S Sale | 2019-12-13 | 2019-12-13 | 3,381 | $49.20 | $166.3K | 121,762 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | M Exercise | 2019-12-13 | 2019-12-13 | 4,129 | $5.00 | $20.6K | 125,143 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | M Exercise | 2019-12-13 | 2019-12-13 | 871 | $4.72 | $4.1K | 121,014 | SEC↗ |
| Becker Daniel J. | Director | P Buy | 2019-11-20 | 2019-11-22 | 55,000 | $29.94 | $1.65M | 667,600 | SEC↗ |
| Goldstein David | Chief Scientific Officer | M Exercise deriv | 2019-11-07 | 2019-11-08 | 1,127 | — | $0 | 0 | SEC↗ |
| Goldstein David | Chief Scientific Officer | M Exercise deriv | 2019-11-07 | 2019-11-08 | 6,147 | — | $0 | 0 | SEC↗ |
| Goldstein David | Chief Scientific Officer | M Exercise deriv | 2019-11-07 | 2019-11-08 | 1,651 | — | $0 | 0 | SEC↗ |
| Goldstein David | Chief Scientific Officer | M Exercise deriv | 2019-11-07 | 2019-11-08 | 1,075 | — | $0 | 14,447 | SEC↗ |
| Goldstein David | Chief Scientific Officer | M Exercise | 2019-11-07 | 2019-11-08 | 1,075 | $3.00 | $3.2K | 39,819 | SEC↗ |
| Goldstein David | Chief Scientific Officer | M Exercise | 2019-11-07 | 2019-11-08 | 6,147 | $1.91 | $11.7K | 37,093 | SEC↗ |
| Goldstein David | Chief Scientific Officer | S Sale | 2019-11-07 | 2019-11-08 | 10,000 | $32.39 | $323.9K | 29,819 | SEC↗ |
| Goldstein David | Chief Scientific Officer | M Exercise | 2019-11-07 | 2019-11-08 | 1,651 | $1.91 | $3.2K | 38,744 | SEC↗ |
| Goldstein David | Chief Scientific Officer | M Exercise | 2019-11-07 | 2019-11-08 | 1,127 | $0.64 | $721 | 30,946 | SEC↗ |
| Becker Daniel J. | Director | P Buy | 2019-10-29 | 2019-10-30 | 9,196 | $33.98 | $312.5K | 612,600 | SEC↗ |
| Becker Daniel J. | Director | P Buy | 2019-10-28 | 2019-10-30 | 68,404 | $33.41 | $2.29M | 603,404 | SEC↗ |
| Becker Daniel J. | Director | P Buy | 2019-10-18 | 2019-10-22 | 535,000 | $28.00 | $14.98M | 535,000 | SEC↗ |
| George Simeon | Director | P Buy | 2019-10-18 | 2019-10-22 | 357,142 | $28.00 | $10.00M | 2,982,855 | SEC↗ |
| GLAXOSMITHKLINE PLC | Other | P Buy | 2019-10-18 | 2019-10-22 | 357,142 | $28.00 | $10.00M | 2,982,855 | SEC↗ |
| Tomasello Shawn | Director | A Award deriv | 2019-08-29 | 2019-08-30 | 20,475 | — | $0 | 20,475 | SEC↗ |
| Tomasello Shawn | Director | A Award deriv | 2019-08-29 | 2019-08-30 | 10,240 | — | $0 | 10,240 | SEC↗ |
| Tomasello Shawn | Director | A Award deriv | 2019-08-29 | 2019-09-04 | 20,475 | — | $0 | 20,475 | SEC↗ |
| New Leaf Ventures II, L.P. | 10% Owner | S Sale | 2019-08-13 | 2019-08-15 | 250,009 | $35.00 | $8.75M | 1,938,167 | SEC↗ |
| New Leaf Ventures II, L.P. | 10% Owner | S Sale | 2019-08-13 | 2019-08-15 | 49,991 | $35.00 | $1.75M | 387,546 | SEC↗ |
| Colowick Alan | Director | A Award deriv | 2019-06-11 | 2019-06-11 | 10,240 | — | $0 | 10,240 | SEC↗ |
| Becker Daniel J. | Director | A Award deriv | 2019-06-11 | 2019-06-11 | 10,240 | — | $0 | 10,240 | SEC↗ |
| George Simeon | Director, 10% Owner | A Award deriv | 2019-06-11 | 2019-06-11 | 10,240 | — | $0 | 10,240 | SEC↗ |
| Lin Shao-Lee | Director | A Award deriv | 2019-06-11 | 2019-06-11 | 10,240 | — | $0 | 10,240 | SEC↗ |
| Machado Patrick | Director | A Award deriv | 2019-06-11 | 2019-06-11 | 20,475 | — | $0 | 20,475 | SEC↗ |
| Machado Patrick | Director | A Award deriv | 2019-06-11 | 2019-06-11 | 10,240 | — | $0 | 10,240 | SEC↗ |
| GLAXOSMITHKLINE PLC | 10% Owner | A Award deriv | 2019-06-11 | 2019-06-17 | 10,240 | — | $0 | 10,240 | SEC↗ |
| OrbiMed Capital GP IV LLC | 10% Owner | S Sale | 2019-05-21 | 2019-05-22 | 1,000,000 | $30.25 | $30.25M | 1,605,713 | SEC↗ |
| Lin Shao-Lee | Director | A Award deriv | 2019-04-16 | 2019-04-18 | 20,475 | — | $0 | 20,475 | SEC↗ |
| Babler Martin | Chief Executive Officer | A Award deriv | 2019-03-01 | 2019-03-08 | 155,000 | — | $0 | 155,000 | SEC↗ |
| CHAI CHRISTOPHER Y | Chief Financial Officer | A Award deriv | 2019-03-01 | 2019-03-08 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Hardiman Roy C. | Chief Business Officer | A Award deriv | 2019-03-01 | 2019-03-08 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Goldstein David | Chief Scientific Officer | A Award deriv | 2019-03-01 | 2019-03-08 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Thomas Dolca | Chief Medical Officer | A Award deriv | 2019-03-01 | 2019-03-08 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Wolff Stefani | Chief Development Officer | A Award deriv | 2019-03-01 | 2019-03-08 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Smither John W | Director | A Award deriv | 2019-02-19 | 2019-02-21 | 20,475 | — | $0 | 20,475 | SEC↗ |
| AKKARAJU SRINIVAS | Director | C Conversion deriv | 2018-09-18 | 2018-09-20 | 208,480 | — | $0 | 0 | SEC↗ |
| GLAXOSMITHKLINE PLC | 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 9,726,783 | — | $0 | 0 | SEC↗ |
| GLAXOSMITHKLINE PLC | 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 2,840,909 | — | $0 | 0 | SEC↗ |
| GLAXOSMITHKLINE PLC | 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 4,942,070 | — | $0 | 0 | SEC↗ |
| GLAXOSMITHKLINE PLC | 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 1,521,895 | — | $0 | 0 | SEC↗ |
| GLAXOSMITHKLINE PLC | 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 2,367,424 | — | $0 | 0 | SEC↗ |
| Babler Martin | Chief Executive Officer | C Conversion deriv | 2018-09-18 | 2018-09-20 | 240 | — | $0 | 0 | SEC↗ |
| Babler Martin | Chief Executive Officer | C Conversion deriv | 2018-09-18 | 2018-09-20 | 240 | — | $0 | 0 | SEC↗ |
| Babler Martin | Chief Executive Officer | C Conversion deriv | 2018-09-18 | 2018-09-20 | 988 | — | $0 | 0 | SEC↗ |
| Babler Martin | Chief Executive Officer | C Conversion deriv | 2018-09-18 | 2018-09-20 | 988 | — | $0 | 0 | SEC↗ |
| Babler Martin | Chief Executive Officer | C Conversion deriv | 2018-09-18 | 2018-09-20 | 988 | — | $0 | 0 | SEC↗ |
| Babler Martin | Chief Executive Officer | C Conversion deriv | 2018-09-18 | 2018-09-20 | 240 | — | $0 | 0 | SEC↗ |
| Gourlay Steve | Chief Medical Officer | C Conversion deriv | 2018-09-18 | 2018-09-20 | 7,269 | — | $0 | 0 | SEC↗ |
| George Simeon | Director, 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 260,617 | — | $0 | 0 | SEC↗ |
| George Simeon | Director, 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 544,047 | — | $0 | 0 | SEC↗ |
| George Simeon | Director, 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 167,537 | — | $0 | 0 | SEC↗ |
| George Simeon | Director, 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 312,741 | — | $0 | 0 | SEC↗ |
| George Simeon | Director, 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 1,070,771 | — | $0 | 0 | SEC↗ |
| New Leaf Ventures II, L.P. | 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 544,047 | — | $0 | 0 | SEC↗ |
| New Leaf Ventures II, L.P. | 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 167,537 | — | $0 | 0 | SEC↗ |
| New Leaf Ventures II, L.P. | 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 260,617 | — | $0 | 0 | SEC↗ |
| New Leaf Ventures II, L.P. | 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 312,741 | — | $0 | 0 | SEC↗ |
| New Leaf Ventures II, L.P. | 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 1,070,771 | — | $0 | 0 | SEC↗ |
| Becker Daniel J. | Director, 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 1,070,771 | — | $0 | 0 | SEC↗ |
| Becker Daniel J. | Director, 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 167,537 | — | $0 | 0 | SEC↗ |
| Becker Daniel J. | Director, 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 544,047 | — | $0 | 0 | SEC↗ |
| Becker Daniel J. | Director, 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 260,617 | — | $0 | 0 | SEC↗ |
| Becker Daniel J. | Director, 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 312,741 | — | $0 | 0 | SEC↗ |
| ORBIMED ADVISORS LLC | 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 1,070,771 | — | $0 | 0 | SEC↗ |
| ORBIMED ADVISORS LLC | 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 312,741 | — | $0 | 0 | SEC↗ |
| ORBIMED ADVISORS LLC | 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 167,537 | — | $0 | 0 | SEC↗ |
| ORBIMED ADVISORS LLC | 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 544,047 | — | $0 | 0 | SEC↗ |
| ORBIMED ADVISORS LLC | 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 260,617 | — | $0 | 0 | SEC↗ |
| Mehra Anand | 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 453,954 | — | $0 | 0 | SEC↗ |
| Mehra Anand | 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 625,482 | — | $0 | 0 | SEC↗ |
| Mehra Anand | 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 521,235 | — | $0 | 0 | SEC↗ |
| Mehra Anand | 10% Owner | C Conversion deriv | 2018-09-18 | 2018-09-20 | 167,537 | — | $0 | 0 | SEC↗ |
| AKKARAJU SRINIVAS | Director | P Buy | 2018-09-18 | 2018-09-20 | 175,000 | $17.00 | $2.98M | 383,480 | SEC↗ |
| AKKARAJU SRINIVAS | Director | C Conversion | 2018-09-18 | 2018-09-20 | 208,480 | — | $0 | 208,480 | SEC↗ |
| GLAXOSMITHKLINE PLC | 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 260,617 | — | $0 | 1,644,129 | SEC↗ |
| GLAXOSMITHKLINE PLC | 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 167,537 | — | $0 | 2,355,713 | SEC↗ |
| GLAXOSMITHKLINE PLC | 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 544,047 | — | $0 | 2,188,176 | SEC↗ |
| GLAXOSMITHKLINE PLC | 10% Owner | P Buy | 2018-09-18 | 2018-09-20 | 270,000 | $17.00 | $4.59M | 2,625,713 | SEC↗ |
| GLAXOSMITHKLINE PLC | 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 312,741 | — | $0 | 1,383,512 | SEC↗ |
| GLAXOSMITHKLINE PLC | 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 1,070,771 | — | $0 | 1,070,771 | SEC↗ |
| Babler Martin | Chief Executive Officer | C Conversion | 2018-09-18 | 2018-09-20 | 240 | — | $0 | 6,732 | SEC↗ |
| Babler Martin | Chief Executive Officer | C Conversion | 2018-09-18 | 2018-09-20 | 240 | — | $0 | 6,732 | SEC↗ |
| Babler Martin | Chief Executive Officer | C Conversion | 2018-09-18 | 2018-09-20 | 988 | — | $0 | 6,492 | SEC↗ |
| Babler Martin | Chief Executive Officer | C Conversion | 2018-09-18 | 2018-09-20 | 240 | — | $0 | 6,732 | SEC↗ |
| Babler Martin | Chief Executive Officer | C Conversion | 2018-09-18 | 2018-09-20 | 988 | — | $0 | 6,492 | SEC↗ |
| Babler Martin | Chief Executive Officer | C Conversion | 2018-09-18 | 2018-09-20 | 988 | — | $0 | 6,492 | SEC↗ |
| Gourlay Steve | Chief Medical Officer | C Conversion | 2018-09-18 | 2018-09-20 | 7,269 | — | $0 | 107,857 | SEC↗ |
| George Simeon | Director, 10% Owner | P Buy | 2018-09-18 | 2018-09-20 | 270,000 | $17.00 | $4.59M | 2,625,713 | SEC↗ |
| George Simeon | Director, 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 1,070,771 | — | $0 | 1,070,771 | SEC↗ |
| George Simeon | Director, 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 312,741 | — | $0 | 1,383,512 | SEC↗ |
| George Simeon | Director, 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 260,617 | — | $0 | 1,644,129 | SEC↗ |
| George Simeon | Director, 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 544,047 | — | $0 | 2,188,176 | SEC↗ |
| George Simeon | Director, 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 167,537 | — | $0 | 2,355,713 | SEC↗ |
| New Leaf Ventures II, L.P. | 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 544,047 | — | $0 | 2,188,176 | SEC↗ |
| New Leaf Ventures II, L.P. | 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 1,070,771 | — | $0 | 1,070,771 | SEC↗ |
| New Leaf Ventures II, L.P. | 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 312,741 | — | $0 | 1,383,512 | SEC↗ |
| New Leaf Ventures II, L.P. | 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 260,617 | — | $0 | 1,644,129 | SEC↗ |
| New Leaf Ventures II, L.P. | 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 167,537 | — | $0 | 167,537 | SEC↗ |
| New Leaf Ventures II, L.P. | 10% Owner | P Buy | 2018-09-18 | 2018-09-20 | 270,000 | $17.00 | $4.59M | 437,537 | SEC↗ |
| Becker Daniel J. | Director, 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 167,537 | — | $0 | 167,537 | SEC↗ |
| Becker Daniel J. | Director, 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 260,617 | — | $0 | 1,644,129 | SEC↗ |
| Becker Daniel J. | Director, 10% Owner | P Buy | 2018-09-18 | 2018-09-20 | 270,000 | $17.00 | $4.59M | 437,537 | SEC↗ |
| Becker Daniel J. | Director, 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 544,047 | — | $0 | 2,188,176 | SEC↗ |
| Becker Daniel J. | Director, 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 1,070,771 | — | $0 | 1,070,771 | SEC↗ |
| Becker Daniel J. | Director, 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 312,741 | — | $0 | 1,383,512 | SEC↗ |
| ORBIMED ADVISORS LLC | 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 167,537 | — | $0 | 2,355,713 | SEC↗ |
| ORBIMED ADVISORS LLC | 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 544,047 | — | $0 | 2,188,176 | SEC↗ |
| ORBIMED ADVISORS LLC | 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 260,617 | — | $0 | 1,644,129 | SEC↗ |
| ORBIMED ADVISORS LLC | 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 312,741 | — | $0 | 1,383,512 | SEC↗ |
| ORBIMED ADVISORS LLC | 10% Owner | C Conversion | 2018-09-18 | 2018-09-20 | 1,070,771 | — | $0 | 1,070,771 | SEC↗ |